LEQEMBI Alzheimer’s Treatment Gets FDA Go Ahead
Phase 2 data showing a reduction in amyloid-beta plaques in early Alzheimer's patients is good enough for FDA to give it temporary approval under their Accelerated Approval pathway.
The positive…